Europe In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry, Genetic Testing, Haematology, Histology andCytolog...
country. Data from 2004 to 2011, forecast forward for 7 years to 2018.- 2011 company shares and distribution shares data f...
5.2 In Vitro Diagnostics, France, Distribution Share (2010-2011) 595.3 In Vitro Diagnostics, France, Company Share (2010-2...
10 In Vitro Diagnostics Market Pipeline Products 17410.1 Clinical Chemisty Market Pipeline Products 17410.2 Immuno Chemist...
2011 42Table 9: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 10: Clinica...
Table 30: Haematology, France, Distribution Share by Revenue ($m), USD Constant, 2010-201172Table 31: Histology And Cytolo...
Constant, 2010-2011 99Table 52: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 201...
132Table 74: Haematology, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 134Table 75: Histology And Cytolog...
Table 96: Microbiology Culture, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 168Table 97: Clinical Chemis...
Cyclase 242Table 128: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant SystemsFor High Pressure Techn...
Table 152: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 268Tab...
Oslo 297Table 180: One Lambda Enters Into Co-Marketing Agreement With CellTrend 298Table 181: InGen BioSciences Enters Int...
LongRange PCR Kit 323Table 205: Denator Enters Into Co-Development Agreement With Erasmus And AmsterdamMedical For Cancer ...
Hospital And University of Oslo 351Table 233: Roche Enters Into Licensing Agreement With Life Technologies For PCR Technol...
2018 43Figure 10: In Vitro Diagnostics, Germany, Company Share (%), 2011 49Figure 11: Clinical Chemistry, Germany, Company...
Upcoming SlideShare
Loading in …5
×

Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

182 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
182
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  1. 1. Europe In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry, Genetic Testing, Haematology, Histology andCytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureReport Details:Published:December 2012No. of Pages: 445Price: Single User License – US$3500Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Genetic Testing,Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureSummaryGlobalData’s new report, “Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry,Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture” provides key market data on the Europe In VitroDiagnostics Market – Germany, France, Italy, Spain and United Kingdom. The report providesvalue (USD million) data for all the market categories – Immuno Chemistry, Clinical Chemistry,Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and GeneticTesting. The report also provides company shares and distribution shares data for each of theaforementioned market categories. The report is supplemented with global corporate-level profilesof the key market participants.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts.Scope- Countries covered include Germany, France, Italy, Spain and United Kingdom.- Market size and company share data for In Vitro Diagnostics market categories – ImmunoChemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture,Histology And Cytology and Genetic Testing.- Annualized market revenues (USD million) data for each of the market categories in each of the
  2. 2. country. Data from 2004 to 2011, forecast forward for 7 years to 2018.- 2011 company shares and distribution shares data for each of the market categories andcountries.- Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnosticsmarket.- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, AbbottLaboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A., SysmexCorporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Alere Inc., DiaSorinS.p.A, Phadia AB and Qiagen N.V.Reasons to buy- Develop business strategies by identifying the key market categories and segments poised forstrong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnosticscompetitive landscape.- Develop capital investment strategies by identifying the key market segments expected toregister strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of productdistribution – Identify, understand and capitalize.Get your copy of this report @http://www.reportsnreports.com/reports/213233-europe-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-microbiology-culture.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 132 Introduction 152.1 What is This Report About? 153 In Vitro Diagnostics in Europe 163.1 In Vitro Diagnostics Cross Country Comparison 163.2 In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 173.3 In Vitro Diagnostics, Europe, Company share (2010-2011) 254 In Vitro Diagnostics In Germany 274.1 In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 274.2 In Vitro Diagnostics, Germany, Distribution Share (2010-2011) 334.3 In Vitro Diagnostics, Germany, Company Share (2010-2011) 375 In Vitro Diagnostics In France 535.1 In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 53
  3. 3. 5.2 In Vitro Diagnostics, France, Distribution Share (2010-2011) 595.3 In Vitro Diagnostics, France, Company Share (2010-2011) 636 In Vitro Diagnostics In United Kingdom 796.1 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 796.2 In Vitro Diagnostics, United Kingdom, Distribution Share (2010-2011) 856.3 In Vitro Diagnostics, United Kingdom, Company Share (2010-2011) 897 In Vitro Diagnostics In Italy 1057.1 In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, 2004-2018 1057.2 In Vitro Diagnostics, Italy, Distribution Share (2010-2011) 1117.3 In Vitro Diagnostics, Italy, Company Share (2010-2011) 1158 In Vitro Diagnostics In Spain 1318.1 In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, 2004-2018 1318.2 In Vitro Diagnostics, Spain, Distribution Share (2010-2011) 1378.3 In Vitro Diagnostics, Spain, Company Share (2010-2011) 1419 Overview of Key Companies in Europe In Vitro Diagnostics Market 1579.1 F. Hoffmann-La Roche Ltd. 1579.2 Siemens Healthcare 1589.3 Abbott Laboratories 1599.4 Beckman Coulter, Inc. 1609.5 Ortho-Clinical Diagnostics Inc. 1619.6 bioMerieux S.A. 1629.7 Sysmex Corporation 1639.8 Bio-Rad Laboratories, Inc. 1639.9 Becton, Dickinson and Company 1649.10 Alere Inc. 1649.11 DiaSorin S.p.A 1659.12 Phadia AB 1659.13 Qiagen N.V. 1669.14 Diagnostica Stago, Inc. 1669.15 Horiba, Ltd. 1679.16 Gen-Probe Incorporated 1679.17 PerkinElmer, Inc. 1689.18 Mindray Medical International Limited 1689.19 Thermo Fisher Scientific Inc. 1699.20 ELITech Group 1699.21 Grifols, S.A. 1709.22 Danaher Corporation 1709.23 Immucor, Inc. 1719.24 Life Technologies Corporation 1719.25 Hologic, Inc. 1729.26 Innogenetics NV 1729.27 Cellestis Limited 173
  4. 4. 10 In Vitro Diagnostics Market Pipeline Products 17410.1 Clinical Chemisty Market Pipeline Products 17410.2 Immuno Chemistry Market Pipeline Products 17710.3 Haematology Market Pipeline Products 18610.4 Infectious Immunology Market Pipeline Products 18810.5 Microbiology Culture Market Pipeline Products 19510.6 Histology And Cytology Market Pipeline Products 19610.7 Genetic Testing Market Pipeline Products 19711 Financial Deals Landscape 20211.1 Acquisition 20211.2 Partnerships 22712 Recent Developments 35712.1 Strategy And Business Planning 35712.2 Research And Development 37312.3 Government and Public Interest 38012.4 Product News 39213 Appendix 42813.1 Definitions of Markets Covered in the Report 42913.2 Research Methodology 43013.3 Secondary Research 43013.4 Primary Research 43113.5 Models 43113.6 Forecasts 43213.7 Expert Panels 43213.8 GlobalData Consulting 43213.9 Currency Conversion 43313.10 Contact Us 43313.11 Disclaimer 4331.1 List of TablesTable 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-2018 28Table 2: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 30Table 3: In Vitro Diagnostics Market, Europe, Cross-Category Analysis, 2004-2018 32Table 4: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Historic, 2004-201134Table 5: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Forecast, 2011-201836Table 6: In Vitro Diagnostics, Europe, Company share by Revenue ($m), USD Constant, 2010-2011 38Table 7: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 40Table 8: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Historic, 2004-
  5. 5. 2011 42Table 9: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 10: Clinical Chemistry, Germany, Distribution Share by Revenue ($m), USD Constant,2010-2011 45Table 11: Genetic Testing, Germany, Distribution Share by Revenue ($m), USD Constant, 2010-2011 45Table 12: Haematology, Germany, Distribution Share by Revenue ($m), USD Constant, 2010-2011 46Table 13: Histology And Cytology, Germany, Distribution Share by Revenue ($m), USD Constant,2010-2011 46Table 14: Immuno Chemistry, Germany, Distribution Share by Revenue ($m), USD Constant,2010-2011 47Table 15: Infectious Immunology, Germany, Distribution Share by Revenue ($m), USD Constant,2010-2011 47Table 16: Microbiology Culture, Germany, Distribution Share by Revenue ($m), USD Constant,2010-2011 48Table 17: In Vitro Diagnostics, Germany, Company Share by Revenue ($m), USD Constant, 2010-2011 50Table 18: Clinical Chemistry, Germany, Company Share by Revenue ($m), USD Constant, 2010-2011 52Table 19: Genetic Testing, Germany, Company Share by Revenue ($m), USD Constant, 2010-2011 54Table 20: Haematology, Germany, Company Share by Revenue ($m), USD Constant, 2010-201156Table 21: Histology And Cytology, Germany, Company Share by Revenue ($m), USD Constant,2010-2011 58Table 22: Immuno Chemistry, Germany, Company Share by Revenue ($m), USD Constant, 2010-2011 60Table 23: Infectious Immunology, Germany, Company Share by Revenue ($m), USD Constant,2010-2011 62Table 24: Microbiology Culture, Germany, Company Share by Revenue ($m), USD Constant,2010-2011 64Table 25: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 66Table 26: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Historic, 2004-201168Table 27: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 70Table 28: Clinical Chemistry, France, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71Table 29: Genetic Testing, France, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71
  6. 6. Table 30: Haematology, France, Distribution Share by Revenue ($m), USD Constant, 2010-201172Table 31: Histology And Cytology, France, Distribution Share by Revenue ($m), USD Constant,2010-2011 72Table 32: Immuno Chemistry, France, Distribution Share by Revenue ($m), USD Constant, 2010-2011 73Table 33: Infectious Immunology, France, Distribution Share by Revenue ($m), USD Constant,2010-2011 73Table 34: Microbiology Culture, France, Distribution Share by Revenue ($m), USD Constant,2010-2011 74Table 35: In Vitro Diagnostics, France, Company Share by Revenue ($m), USD Constant, 2010-2011 76Table 36: Clinical Chemistry, France, Company Share by Revenue ($m), USD Constant, 2010-2011 78Table 37: Genetic Testing, France, Company Share by Revenue ($m), USD Constant, 2010-201180Table 38: Haematology, France, Company Share by Revenue ($m), USD Constant, 2010-2011 82Table 39: Histology And Cytology, France, Company Share by Revenue ($m), USD Constant,2010-2011 84Table 40: Immuno Chemistry, France, Company Share by Revenue ($m), USD Constant, 2010-2011 86Table 41: Infectious Immunology, France, Company Share by Revenue ($m), USD Constant,2010-2011 88Table 42: Microbiology Culture, France, Company Share by Revenue ($m), USD Constant, 2010-2011 90Table 43: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-201892Table 44: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,2004-2011 94Table 45: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,2011-2018 96Table 46: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 97Table 47: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Constant,2010-2011 97Table 48: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Constant,2010-2011 98Table 49: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 98Table 50: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 99Table 51: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD
  7. 7. Constant, 2010-2011 99Table 52: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 100Table 53: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 102Table 54: Clinical Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 104Table 55: Genetic Testing, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 106Table 56: Haematology, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 108Table 57: Histology And Cytology, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 110Table 58: Immuno Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 112Table 59: Infectious Immunology, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 114Table 60: Microbiology Culture, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 116Table 61: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, 2004-2018 118Table 62: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, Historic, 2004-2011120Table 63: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, Forecast, 2011-2018122Table 64: Clinical Chemistry, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011123Table 65: Genetic Testing, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011123Table 66: Haematology, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011 124Table 67: Histology And Cytology, Italy, Distribution Share by Revenue ($m), USD Constant,2010-2011 124Table 68: Immuno Chemistry, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011 125Table 69: Infectious Immunology, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011 125Table 70: Microbiology Culture, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011 126Table 71: In Vitro Diagnostics, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011128Table 72: Clinical Chemistry, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011130Table 73: Genetic Testing, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011
  8. 8. 132Table 74: Haematology, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 134Table 75: Histology And Cytology, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 136Table 76: Immuno Chemistry, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011138Table 77: Infectious Immunology, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 140Table 78: Microbiology Culture, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 142Table 79: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, 2004-2018 144Table 80: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, Historic, 2004-2011146Table 81: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, Forecast, 2011-2018148Table 82: Clinical Chemistry, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011 149Table 83: Genetic Testing, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011149Table 84: Haematology, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011150Table 85: Histology And Cytology, Spain, Distribution Share by Revenue ($m), USD Constant,2010-2011 150Table 86: Immuno Chemistry, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011 151Table 87: Infectious Immunology, Spain, Distribution Share by Revenue ($m), USD Constant,2010-2011 151Table 88: Microbiology Culture, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011 152Table 89: In Vitro Diagnostics, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 154Table 90: Clinical Chemistry, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011156Table 91: Genetic Testing, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011158Table 92: Haematology, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 160Table 93: Histology And Cytology, Spain, Company Share by Revenue ($m), USD Constant,2010-2011 162Table 94: Immuno Chemistry, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 164Table 95: Infectious Immunology, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 166
  9. 9. Table 96: Microbiology Culture, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 168Table 97: Clinical Chemisty Market Pipeline Products 186Table 98: Immuno Chemistry Market Pipeline Products 189Table 99: Haematology Market Pipeline Products 198Table 100: Infectious Immunology Market Pipeline Products 200Table 101: Microbiology Culture Market Pipeline Products 207Table 102: Histology And Cytology Market Pipeline Products 208Table 103: Genetic Testing Market Pipeline Products 209Table 104: Amgen To Acquire Decode Genetics, Human Genetics Company, For $415 Million 214Table 105: VWR International Acquires Labonord, Histology Reagents Supplier 216Table 106: VWR International Acquires Switch, Cytology And Histology Reagents Manufacturer217Table 107: Trivitron Healthcare Acquires Ani Labsystems For $20.3 Million 218Table 108: Exonhit To Acquire InGen BioSciences From Innoven Partenaires And Amundi PrivateEquity For $23 Million 219Table 109: Erba Lachema Acquires Maxmat, Maker Of Automated Analyzers And Reagents 221Table 110: Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro FertilizationScreening Solutions 222Table 111: Sias To Acquire Xiril, Lab Equipment Maker 223Table 112: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 224Table 113: Abingdon Health Acquires 80% Stake In Forsite Diagnostics 226Table 114: Agilent Technologies Completes Acquisition Of Dako From EQT For $2.2 Billion 227Table 115: Ametek Completes Acquisition Of Dunkermotoren From Triton Advisers For $330Million 229Table 116: Abingdon Health To Acquire 50.1% Stake In Molecular Vision From ImperialInnovations Group 230Table 117: Trinity Biotech To Acquire Fiomi Diagnostics From Alfven & Didrikson For $13.1 Million231Table 118: Unisense FertiliTech Plans Sale Of The Company 232Table 119: Echosens Acquires BioLiveScale, Provider Of Biomarkers For Liver Diseases 233Table 120: Harvard Bioscience Acquires AHN Biotechnologie, Maker Of Plastic Consumable LabProducts, For $2.6 Million 234Table 121: B. Braun Melsungen Acquires 20% Stake In CeGaT 235Table 122: Addtech Life Science Acquires Reagent And Instrument Firm, BioNordika Group 236Table 123: Quintiles Acquires Minority Stake In Oxford Cancer Biomarkers For $5 Million 237Table 124: Eppendorf Acquires Dasgip Group, Developer Of Bioreactor Systems 238Table 125: Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems239Table 126: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs ForTranscreener Epigen Methyltransferase Assay 240Table 127: Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl
  10. 10. Cyclase 242Table 128: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant SystemsFor High Pressure Technologies 243Table 129: BioCat Enters Into Distribution Agreement With Alpco Diagnostics For ELISA Kits 244Table 130: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology245Table 131: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery246Table 132: Scienion Enters Into Co-Development Agreement With Genomica 247Table 133: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 248Table 134: Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test InOncology 249Table 135: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 250Table 136: Phthisis Diagnostics Enters Into Distribution Agreement With Elitech Group 251Table 137: BioDot Enters Into Co-Marketing Agreement With JOT Automation 252Table 138: Merck Serono Enters Into Co-Development Agreement With Auxogyn For EarlyEmbryo Viability Assessment Test 253Table 139: AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies254Table 140: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 255Table 141: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx256Table 142: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For DigitalMicroscopy Hematology Solutions 257Table 143: Med BioGene Amends Licensing Agreement With Precision Therapeutics ForLungExpress Dx Test 258Table 144: Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux ForProcalcitonin Testing 259Table 145: Ovizio Imaging Systems Enters Into Distribution Agreement With ApplikonBiotechnology 261Table 146: Curetis Enters Into Co-Development Agreement With Heraeus Medical For Unyvero262Table 147: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 263Table 148: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For MaverickDetection Platform 264Table 149: CML HealthCare Enters Into Agreement With MaRS Innovation 265Table 150: Akrivis Technologies Enters Into Co-Development Agreement With United StatesBiological 266Table 151: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery267
  11. 11. Table 152: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 268Table 153: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 269Table 154: GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 270Table 155: Dolomite Centre Enters Into Licensing Agreement With Japan Science and TechnologyAgency For Microdroplet Generation Technology 271Table 156: InGen BioSciences Enters Into Distribution Agreement With Quidel 272Table 157: InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids 273Table 158: University of Limerick Enters Into Co-Development Agreement With GenCell 274Table 159: NewBridge Pharma Enters Into Licensing Agreement With Genomic Health ForOncotype DX Tests 275Table 160: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 277Table 161: Epistem Enters Into Distribution Agreement With Becton Dickinson For MycobacteriumTB Test 278Table 162: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 279Table 163: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 280Table 164: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 281Table 165: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 282Table 166: BioView Enters Into Co-Development Agreement With ScreenCell For CirculatingTumor Cell Analysis Technology 283Table 167: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test284Table 168: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 285Table 169: Lab21 Enters Into Co-Development Agreement With Pharma Company 286Table 170: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis BiomarkersFor DNA-FISH Assays 287Table 171: Courtagen Life Sciences Enters Into Licensing Agreement With Scienion ForsciFlexArrayer Technology 288Table 172: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening ForAdenoPlus 289Table 173: Leica Microsystems Enters Into Integration Agreement With Indica Labs 291Table 174: ImaBiotech Enters Into Agreement With Genfit 292Table 175: Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab ForSeptin9 Biomaker 293Table 176: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 294Table 177: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4POC Test 295Table 178: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 296Table 179: RayBiotech Enters Into Agreement With Oslo University Hospital And University of
  12. 12. Oslo 297Table 180: One Lambda Enters Into Co-Marketing Agreement With CellTrend 298Table 181: InGen BioSciences Enters Into Co-Marketing Agreement With Cylex For ImmuKnowAssays 299Table 182: BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 300Table 183: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientificand Industrial Research 301Table 184: Foundation Medicine Extends Co-Development Agreement With Novartis 302Table 185: Sebia Enters Into Co-Development Agreement With Institut National de la Sante AndInserm Transfert 303Table 186: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight GeneticsFor ALK Cancer Biomarker 304Table 187: Ventana Medical Enters Into Licensing Agreement With German Cancer ResearchCenter And University Hospital Heidelberg For BRAF V600E 305Table 188: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 307Table 189: Radisens Diagnostics Enters Into Co-Development Agreement With Beckman CoulterFor HDR Detection Technology 308Table 190: Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 309Table 191: Biocartis Enters Into Co-Development Agreement With Wellcome Trust SangerInstitute And Philips Research Europe For Oncology Diagnostics 310Table 192: Seegene Enters Into Co-Development Agreement With DuPont Nutrition & Health ToDevelop Multiplexed Assays For Food Safety Testing 311Table 193: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERGMarker 312Table 194: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating TumorCell Technology 313Table 195: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 314Table 196: Dako Announces Licensing Agreement With Van Andel Research Institute For CancerDiagnostic Tool 315Table 197: Isogen Life Science Enters Into Co-Marketing Agreement With Axela For BiomarkerAnalysis Platforms 316Table 198: Multiplicom Enters Into Co-Development Agremment With Institute forCardiometabolism And Institut Du Cerveau 317Table 199: Opko Health Enters Into Licensing Agreement With International Health TechnologyFor Prostate Cancer Biomarker Panel 318Table 200: ZyGem Enters Into Co-Marketing Agreement With Tataa Biocenter 319Table 201: Dolomite Centre Enters Into Co-Development Agreement With LioniX 320Table 202: Applied Microarrays Enters Into Co-Development Agreement With Sensovation ForFlexiPlex Array System 321Table 203: Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For VerigeneProducts 322Table 204: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
  13. 13. LongRange PCR Kit 323Table 205: Denator Enters Into Co-Development Agreement With Erasmus And AmsterdamMedical For Cancer Biomarker Platform 324Table 206: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 325Table 207: Novo Nordisk Enters Into Co-Development Agreement With Oxford University 326Table 208: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 327Table 209: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 328Table 210: GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 329Table 211: Sysmex Extends Distribution Agreement With Roche 330Table 212: Rubicon Genomics Enters Into Technology Integration Agreement With KreatechDiagnostics 331Table 213: NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 332Table 214: Elchrom Scientific Enters Into Technology Integration Agreement With Biotium 333Table 215: RayBiotech Enters Into Co-Marketing Agreement With Innopsys 334Table 216: LAB21 Enters Into Co-Development Agreement With IVD Company For AspergillusMolecular Assay 335Table 217: Randox Labs Enters Into Licensing Agreement With Proteome Sciences For StrokeBiomarker 336Table 218: Bernhard Nocht Institute Enters Into Co-Development Agreement With altonaDIAGNOSTICS 337Table 219: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 338Table 220: Accuray Enters Into Co-Development Agreement With University of Heidelberg 339Table 221: A*STAR Enters Into Co-Development Agreement With QuantuMDx Group 340Table 222: DiaGenic Enters Into Co-Development Agreement With GE Healthcare 341Table 223: DNA Electronics Enters Into Licensing Agreement With Gene Onyx For GenalysisTechnology 342Table 224: Protagen Enters Into Co-Development Agreement With University of Tuebingen 343Table 225: Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 344Table 226: Saladax Biomedical Enters Into Co-Marketing Agreement With INyDIA LaboratoriosBiomedical Diagnostics For My5-FU 345Table 227: Hamilton Thorne Expands Co-Marketing Agreement With Leica Microsystems 346Table 228: ANGLE Enters Into Co-Development Agreement With Paterson Institute for CancerResearch 347Table 229: Yissum Research Development Company Enters Into Licensing Agreement WithBioConnections For Commercialization Of Kits 348Table 230: Radisens Enters Into Licensing Agreement With Tecan 349Table 231: Apceth Enters Into Co-Development Agreement With Indivumed For BiomarkerPlatform 350Table 232: Oxford Gene Technology Enters Into Licensing Agreement With Oslo University
  14. 14. Hospital And University of Oslo 351Table 233: Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology352Table 234: Dako Enters Into Co-Development Agreement With Amgen 353Table 235: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based BiomarkersFor Cancer 354Table 236: Integromics Enters Into Co-Development Agreement With Galician Foundation OfGenomic Medicine 355Table 237: Horizon Diagnostics Enters Into Licensing Agreement With UK NEQAS 356Table 238: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCTAssay For Sepsis 357Table 239: Crossbeta Biosciences, Good Biomarker Sciences And U-Protein Express Partner ToDevelop Alzheimer’s Disease Biomarker 358Table 240: OPKO Health Enters Into Licensing Agreement With Arctic Partners For Biomakers359Table 241: Roche Enters Into Co-Development Agreement With Technoclone 360Table 242: Dako Enters Into Co-Development Agreement With Amgen 361Table 243: Foundation Medicine Enters Into Co-Development Agreement With Sanofi For GeneticBiomarkers And Potential Diagnostics 362Table 244: QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 363Table 245: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 364Table 246: Boulder Diagnostics Enters Into Licensing Agreement With RUNMC 365Table 247: HansaBioMed, Poliedra Sanita, Siena Biotech And Biofund Partner To FormExosomics Siena 366Table 248: Global BioDiagnostics Extends Co-Development Agreement With Foundation forInnovative New Diagnostics 367Table 249: Sony DADC Enters Into Co-Development Agreement With Axela 3681.2 List of FiguresFigure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-2018 28Figure 2: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 29Figure 3: In Vitro Diagnostics Market, Europe, Cross-Category Analysis, 2004-2018 31Figure 4: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Historic, 2004-201133Figure 5: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 35Figure 6: In Vitro Diagnostics, Europe, Company share (%), 2011 37Figure 7: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 39Figure 8: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Historic, 2004-2011 41Figure 9: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Forecast, 2011-
  15. 15. 2018 43Figure 10: In Vitro Diagnostics, Germany, Company Share (%), 2011 49Figure 11: Clinical Chemistry, Germany, Company Share (%), 2011 51Figure 12: Genetic Testing, Germany, Company Share (%), 2011 53Figure 13: Haematology, Germany, Company Share (%), 2011 55Figure 14: Histology And Cytology, Germany, Company Share (%), 2011 57Figure 15: Immuno Chemistry, Germany, Company Share (%), 2011 59Figure 16: Infectious Immunology, Germany, Company Share (%), 2011 61Figure 17: Microbiology Culture, Germany, Company Share (%), 2011 63Figure 18: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 65Figure 19: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Historic, 2004-201167Figure 20: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 69Figure 21: In Vitro Diagnostics, France, Company Share (%), 2011 75Figure 22: Clinical Chemistry, France, Company Share (%), 2011 77Figure 23: Genetic Testing, France, Company Share (%), 2011 79Figure 24: Haematology, France, Company Share (%), 2011 81Figure 25: Histology And Cytology, France, Company Share (%), 2011 83Figure 26: Immuno Chemistry, France, Company Share (%), 2011 85Figure 27: Infectious Immunology, France, Company Share (%), 2011 87Figure 28: Microbiology Culture, France, Company Share (%), 2011 89Figure 29: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 91Figure 30: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,2004-2011 93Figure 31: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,2011-2018 95Figure 32: In Vitro Diagnostics, United Kingdom, Company Share (%), 2011 101Figure 33: Clinical Chemistry, United Kingdom, Company Share (%), 2011 103Figure 34: Genetic Testing, United Kingdom, Company Share (%), 2011 105Figure 35: Haematology, UContact: sales@reportsandreports.com for more information.

×